v3.26.1
Segment Reporting - Summary of Operating Financial Results (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]            
Total revenue $ 0   $ 0   $ 0 $ 0
Significant segment expenses:            
Research and development expense 174   935   486 1,743
General and administrative expense 889   1,514   2,180 3,731
Loss (Gain) on disposal of assets (9)   60   28 86
Gain on lease termination 0   0   0 (5,974)
Total operating expenses 1,054   2,509   2,694 (414)
Gain on settlement of accounts payables 0   0   0 191
Change in fair value of contingent liability (52)   (159)   (240) (295)
Other income (expense) (26)   (9)   (26) (9)
Total other expense, net (67)   (112)   (255) (25)
Net (loss) income (1,121) $ (1,828) (2,621) $ 3,010 (2,949) 389
Biotechnology Segment            
Segment Reporting [Line Items]            
Total revenue 0   0   0 0
Significant segment expenses:            
Research and development expense 174   935   486 1,743
General and administrative expense 889   1,514   2,180 3,731
Loss (Gain) on disposal of assets (9)   60   28 86
Gain on lease termination 0   0   0 (5,974)
Total operating expenses (1,054)   (2,509)   (2,694) 414
Interest and dividend income 11   56   11 88
Gain on settlement of accounts payables 0   0      
Change in fair value of contingent liability (52)   (159)   (240) (295)
Other income (expense) (26)   (9)   (26) 182
Total other expense, net (67)   (112)   (255) (25)
Net (loss) income $ (1,121)   $ (2,621)   $ (2,949) $ 389